Version history

1 version on record. Newest first; the live version sits at the top with a live indicator.

  1. Live
    4/11/2026, 7:25:53 AM
    Content snapshot 
    {
  "description": "Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engineering improved BBB transcytosis via transferrin receptor, LRP1, or novel shuttle peptides could dramatically improve efficacy.\n\nLinked to 5 hypotheses and 5 targets.",
  "gap_id": "gap-008",
  "mission_id": "neurodegeneration",
  "challenge_type": "open",
  "scope": "gap",
  "initial_bounty_usd": 193000,
  "current_bounty_usd": 196382.4,
  "bounty_confidence": 0.65,
  "gap_importance_score": 0.5,
  "urgency_score": 0.4,
  "market_price": 0.5,
  "composite_score": 0.47,
  "debate_count": 0,
  "status": "open"
}